💉
Therapeutics
What the Latest Research Reveals
Data last updated: 31 studies cited
How this page is produced
Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.
KEY FINDINGS
Paxlovid for Long COVID
No benefit
95% CI: p=0.38 vs placebo at 10 weeks
Source [5]
Vaccination Protection
-50%
95% CI: OR 0.5 (95% CI: 0.4-0.6)
Source [25]
Reinfection Risk
+100-150%
95% CI: HR 2.0-2.5 per infection
Source [13]
LDN Response Rate
30-50%
95% CI: Fatigue improvement in observational studies
Source [15]
Goal attainment improvement with cognitive rehabilitation vs treatment as usual at 3 months
Cohen d = 1.57
95% CI: 95% CI: 2.03-3.73
Source [31]
Sustained goal attainment improvement with cognitive rehabilitation at 6 months
Cohen d = 0.91
95% CI: 95% CI: 0.86-2.57
Source [31]
THE TIMELINE
Acute Phase
0-4 weeks
Subacute Phase
4-12 weeks
Chronic Phase
3-12 months
Long-Term
>12 months
Acute Phase
0-4 weeks
Paxlovid within 5 days may prevent Long COVID
Key Event
Antiviral treatment window
Post-Viral Research Investment
Long COVID$1.15B (RECOVER)
ME/CFS (pre-pandemic)$15M/year
Source: NIH funding data comparison
Cumulative Long COVID Risk with Reinfection
1 infection+10-30%
2 infections+20-40%
3+ infections+Further increased
“Each reinfection carries additive risk of Long COVID and organ damage”
THE HOPEFUL HORIZON
- 35-50% of patients spontaneously recover within 6 months[4]
- Low-dose naltrexone shows 30-50% response rates for fatigue[15]
- Vaccination reduces Long COVID risk by 40-50%[25]
- Over 200 clinical trials actively investigating treatments[0]
SOURCES
- [1]Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. DOI (opens in new tab)
- [2]Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-1607. DOI (opens in new tab)
- [3]Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-1615. DOI (opens in new tab)
- [4]Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-461. DOI (opens in new tab)
- [5]RECOVER Consortium. RECOVER-VITAL: Paxlovid for Post-Acute Sequelae of SARS-CoV-2 Infection. N Engl J Med. 2024.
See a problem with the Therapeutics research summary?
Send a source correction or freshness concern. We cannot provide personal medical advice through this site.
Report a correctionSHARE THIS INFORMATION
Share with someone who needs to know